Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®
Vivos Inc (OTCQB: RDGL) announced on October 27, 2025 that it retained Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as lead regulatory advisors to support its FDA Investigational Device Exemption (IDE) submission for RadioGel®.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivos Inc (OTCQB: RDGL) announced on October 27, 2025 that it retained Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as lead regulatory advisors to support its FDA Investigational Device Exemption (IDE) submission for RadioGel®. The company said Dr. Smith has direct experience with the FDA Division reviewing radiological devices and will help address remaining IDE deficiencies.
RadioGel® is described as an injectable, high‑dose, localized radiation device intended for tumors. Securing IDE approval is stated as a critical step toward initiating U.S. clinical trials at the Mayo Clinic. RadioGel® is not yet authorized for pre‑market use.
Positive
- Retained experienced FDA regulatory lead (Dr. John J. Smith)
- Advisors familiar with RadioGel® and FDA review panel
- Move intended to address remaining IDE deficiencies
Negative
- RadioGel® is not authorized for pre‑market use
- IDE submission currently has remaining deficiencies
Details
News Market Reaction – RDGL
On Oct 27, the day this news came out, RDGL closed 3.17% above the previous close.
Data tracked by StockTitan Argus for the Oct 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Richland, WA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced today that they have appointed Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead regulatory advisors for its FDA Investigational Device Exemption (IDE) submission for RadioGel®.
Dr. Smith, a board-certified diagnostic radiologist and former associate professor at Harvard Medical School, is widely recognized as one of the nation’s leading FDA regulatory consultants in the medical device sector. He is currently a partner in the Global Regulatory group at Hogan Lovells, based in Washington, D.C.
“We are excited to re-engage Dr. Smith—someone we have worked with before and who is very familiar RadioGel®, said Dr. Michael Korenko, CEO of Vivos Inc. He brings not only unmatched expertise but current, first-hand experience with the FDA’s Division of Radiological Imaging and Radiation Therapy Devices review panel where we are working through the remaining deficiencies in our IDE submission. Bringing Dr. Smith and his team on-board positions us to move forward with confidence and clarity.”
Vivos’ RadioGel® is a groundbreaking injectable device designed to deliver a high-dose, localized, targeted radiation safely and effectively to tumors. Securing IDE approval remains a critical step toward initiating U.S. clinical trials at the Mayo Clinic. RadioGel® is not yet authorized for pre-market use.
Mike Korenko, ScD
CEO Vivos Inc
Contact:
Investor Relations
Vivos Inc.
Email: info@vivosinc.com
Website: www.vivosinc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.